← Back to Search

Janus Kinase (JAK) Inhibitor

ruxolitinib cream for Atopic Dermatitis (SCRATCH-AD Trial)

Phase 2
Waitlist Available
Research Sponsored by Incyte Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline; day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
Awards & highlights

SCRATCH-AD Trial Summary

This trial will test whether a drug called ruxolitinib can help relieve itch in people with atopic dermatitis.

Eligible Conditions
  • Atopic Dermatitis

SCRATCH-AD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline; day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline; day 1 (15 and 30 minutes postdose; 1, 2, 4, 6, and 12 hours postdose) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change From Baseline in the Peak-Pruritus Numerical Rating Scale (PP-NRS) Score at Day 2 (24-hour Recall Period After First Application)
Secondary outcome measures
Change From Baseline in Investigator Global Assessment (IGA) at Day 8, Day 15, and Day 29
Change From Baseline in the Modified Peak-Pruritus Numerical Rating Scale (mPP-NRS) Score (Current Itch Intensity) at 15 and 30 Minutes Postdose and at 1, 2, 4, 6, and 12 Hours Postdose on Day 1
Change From Baseline in the PP-NRS Score From Day 3 Through Day 29 (24-hour Recall Period After First Application)
+9 more

Side effects data

From 2022 Phase 2 trial • 49 Patients • NCT04839380
6%
COVID-19
4%
Headache
4%
Upper respiratory tract infection
4%
Back pain
4%
Nasopharyngitis
2%
Gastroenteritis
2%
Rhinitis allergic
2%
Epistaxis
2%
Wound haemorrhage
2%
Eye pruritus
2%
Urinary tract infection
2%
Concussion
2%
Acne
2%
Molluscum contagiosum
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ruxolitinib 1.5% Cream BID

SCRATCH-AD Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment Group : RuxolitinibExperimental Treatment1 Intervention
ruxolitinib cream 1.5% will be applied twice daily as a thin film.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ruxolitinib cream
2021
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Incyte CorporationLead Sponsor
365 Previous Clinical Trials
55,140 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

How old are they?
18 - 65
What site did they apply to?
Innovoderm Research
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
2021. "The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04839380.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top